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The induction in rat liver of a specific variant(s) of cytochrome P450 (PB-P450) by phenobarbital nd its 
repression by ,&naphthoflavone occur through corresponding changes in the levels of mRNA coding for 
the protein(s). The level of translatable mRNA coding for NADPH-cytochrome P450 reductase inrat liver 
increases on treatment with phenobarbital but not @-naphthoflavone. 
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1. INTRODUCTION 
Cytochromes P450 and NADPH cytochrome 
P450 reductase are two major components of the 
mixed function monooxygenase systems of liver 
microsomal membranes. The enzyme systems are 
involved in the metabolism of xenobiotics, in- 
cluding drugs and carcinogens, as well as en- 
dogenous substrates such as steroid hormones 
[l-6]. A variety of xenobiotics increase the level of 
total cytochromes P450, the actual variants of 
cytochromes P450 induced depending on the 
xenobiotic used [7-91. Radioimmunoassays [8, lo] 
for a specific variant have shown that phenobar- 
bital (PB) increases the levels of the major PB- 
inducible cytochrome P450 variant (PB P450) and 
NADPH cytochrome P450 reductase 43- and 
2.6-fold, respectively. However, treatment of 
animals with fi-naphthoflavone (,&NF) (an inducer 
of different cytochrome P450 variants) [8] resulted 
in a 55% decrease in the amount of PB P450 and 
had no effect on the amount of NADPH 
Abbreviations: PB, phenobarbital; P-NF, P- 
naphthoflavone; PB P450, major inducible cytochrome 
P450 variant of M, 52 000 
,&Naphthojlavone 
cytochrome P450 reductase. Induction of PB P450 
by PB involves an increase in the amount of 
translatable mRNA coding for this protein [ll]. 
Here, we investigate the mechanism of repression 
of PB P450 protein by &NF and the molecular 
basis of the differential effect of PB and ,&NF 
on the expression of NADPH cytochrome P450 
reductase. 
2. MATERIALS AND METHODS 
2.1. Animals 
Male Sprague-Dawley rats (180-200 g body wt) 
bred at University College Animal facility were us- 
ed in these experiments. Treatment of animals with 
sodium phenobarbital or ,&naphthoflavone is in 
PI. 
2.2. Isolation of RNA 
Total rat liver RNA was isolated from the livers 
of PB-treated, &NF-treated and control animals as 
in [12]. Poly(A)+-containing RNA was isolated by 
a modification of the method in [13]. Total RNA 
was adjusted to 1 mg/ml in 10 mM Tris-HCl 
(pH 7.5), 1 mM EDTA, 0.1% (w/v) SDS, 0.5 M 
NaCl (buffer A) and heated at 68°C for 2 min and 
chromatographed on a column of oligo(dT)- 
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cellulose (PL Biochemicals, type 7). The entire 
eluate was reloaded onto the column which was 
then washed with buffer A until the &a0 returned 
to zero. Poly(A)+ RNA was eluted with 10 mM 
Tris-HCl (pH 7.5), 1 mM EDTA, 0.1% (w/v) 
SDS. Fractions containing poly(A)+ RNA were ad- 
justed to 0.5 M with respect to NaCl, treated at 
68°C for 2 min and rechromatographed on 
oligo(dT)-cellulose. The column was washed and 
poly(A)+ RNA was eluted as above. Poly(A)+ 
RNA was adjusted to 0.25 M with respect to 
sodium acetate (pH 6.0), mixed with 2.5 vol. ab- 
solute ethanol and stored at - 20°C overnight. Po- 
ly(A)+ RNA was pelleted at 16 000 x g for 10 min 
at - lO”C, resuspended in water and reprecipitated 
as above. Final RNA pellets were washed twice 
with 90% ethanol, dried under a stream of 
nitrogen, and resuspended in water at 
-4.5 mg/ml. 
P450; M, 52 000), and NADPH cyt. P450 reduc- 
tase (Mr 76 000) were isolated from the livers of 
PB-treated rats as in [14]. Antibodies to these two 
proteins were raised in rabbits as in [8]. 
3. RESULTS 
3.1. Effect of phenobarbital and ,&naphtho- 
flavone treatment on products of ttxnslation 
in vitro 
Poly(A)+ RNA isolated from the livers of PB,,& 
NF and untreated animals were translated in vitro 
in a rabbit reticulocyte cell free system. The spec- 
trum of proteins synthesized by each RNA sample 
was analysed by SDS-polyacrylamide gel elec- 
trophoresis and fluorography. The overall patterns 
of protein synthesis directed by poly(A)+ mRNA 
2.3. Preparation of polyribosomes 
Polyribosomes were prepared from rat liver as in 
[ill. 
2.4. Translation in vitro 
Polyribosomes, total RNA and poly(A)+ RNA 
were translated in vitro using a rabbit reticulocyte 
lysate (Amersham International, Bucks) as in [l 11. 
Total translation products were analysed on 
SDS-IO% polyacrylamide gels as in [l 11. 
2.5. Immunoprecipitation 
Immunoprecipitation of translation products 
was as in [ 1 l] except that translation products (see 
figure legends for cpm used) were made 1% (w/v) 
with respect to both sodium deoxycholate and 
Triton X-100, centrifuged at 10 000 x g for 
10 min and diluted to 900 ,uI with a solution con- 
taining 1% (w/v) sodium deoxycholate, 1% (w/v) 
Triton X-100/150 mM NaCI/S mM EDTA/SO mM 
Tris-HCI (pH 7.4)/0.02% (w/v) NaNJ2 mM me- 
thionine/l mM phenylmethanesulphonyl fluoride 
before addition of the appropriate antibody. Im- 
munoprecipitated polypeptides were analysed by 
SDS-polyacrylamide gel electrophoresis and quan- 
titated as in [ 111. 
2.6. Purification of proteins and preparation of 
antibodies 
Fig. 1. SDS-polyacrylamide gel electrophoresis 
demonstrating the differential effects of PB and ,&NF on 
translatable PB P450 mRNA. Total translation products 
(tracks a-c) contained 4 x lo4 acid-precipitable cpm. 
For immunoprecipitation analysis (tracks d-j) 6 x lo5 
(tracks d-f,h) 4 x lo5 (track g) or 4 x lo6 (tracks i,j) 
acid-precipitable cpm of translation products were in- 
cubated with 10 ~1 non-immune serum (track d) or 10 ,J 
of anti(PB P450) serum (tracks e-j) and processed as in 
section 2.5. Translation products were from poly(A)’ 
RNA isolated from ,&NF- (tracks a,e,j), PB- (tracks 
b,d,g,h) or un-treated (tracks c,f,i) rats. Numbers give 
M, of marker proteins (x 10m3) (k). Samples i-k were 
The major PB-inducible cytochrome P450 (PB electrophoresed on a separate gel to samples a-h. 
376 
Volume 150. number 2 FEBS LETTERS December 1982 
isolated from PB-,&NF and untreated animals are 
very similar (fig. la-c). As shown in [ll] PB treat- 
ment causes an increase in the translation of an Mr 
52 000 polypeptide (fig. lb), which corresponds to 
the major inducible cytochrome P450 (PB P450) 
[8,11]. However, ,&NF treatment increased the 
translation of an Mr 54 000 polypeptide correspon- 
ding to the major ,&NF-inducible cyt. P450 [8]. In 
addition, ,&NF treatment caused a decrease visual- 
ly in the quantity of an M, 52 000 polypeptide 
(fig. la, cf. fig. lc). This result suggested that the 
observed decrease in the amount of PB P450 in 
microsomal membranes following ,&NF treatment 
[8] may involve a decrease in the amount of the 
mRNA coding for PB P450. To investigate this 
possibility, we quantified the amount of PB P450 
mRNA present in RNA isolated from PB-,&NF- 
and un-treated rats. 
3.2. Quantification of PB P4SO mRNA in 
poly(A)+ RNA 
We have shown by immunoprecipitation using 
antibodies specific for PB P450 that PB treatment 
causes an -20-fold increase in the amount of 
translatable mRNA coding for this protein [l 11. 
We have now extended these studies to analyse the 
effect of a different xenobiotic on the amount of 
translatable PB P450 mRNA. Anti-(PB P450) an- 
tiserum precipitated PB P450 from the translation 
products of poly(A)+ RNA isolated from PB- 
treated rats (fig. lg,h). No PB P450 was visibly 
precipitated from the translation products of 
poly(A)+ RNA isolated from control (fig. If) or 
fl-NF-treated (fig. lc) rats. To ensure the accurate 
quantitation of the small amounts of translatable 
PB P450 mRNA present in the livers of control and 
P-NF-treated animals the quantity of translation 
products used in the immunoprecipitation was in- 
creased from 6 x lo’-4 x lo6 acid-precipitable 
cpm (fig. li,j). PB P450 mRNA was quantified by 
determining the radioactivity incorporated into the 
Mr 52 000 immunoprecipitated polypeptide and ex- 
pressing this as a percentage of the total acid- 
precipitable radioactivity [ 111. PB P450 
represented 0.63070, 0.029% and 0.015% of the 
proteins synthesized by poly(A)+ RNA isolated 
from the livers of PB-treated, untreated, or ,&NF- 
treated rats, respectively. It should be noted that 
PB P450 mRNA represented 0.029% of poly(A)+ 
RNA isolated from control animals whether 6 x 
10’ cpm or 4 x lo6 cpm were included in the im- 
munoprecipitation reaction. However, when only 6 
x lo5 cpm were analysed it was not possible to 
detect any PB P450 in the translation products of 
poly(A)+ RNA isolated from ,&NF-treated rats. 
The results demonstrate that the amount of 
translatable PB P450 poly(A)+ mRNA increased 
22-fold on treatment with PB but decreased by 
-5r(% on treatment with /3-NF. This decrease in 
mRNA is very similar to the decrease we found in 
PB P450 in the liver microsomal membranes of ,f3- 
NF-treated rats [8]. 
3.3. Quantification of NADPH cytochrome P450 
reductase mRNA 
We have also investigated the different effects of 
PB and ,&NF on the amount of translatable 
mRNA coding for NADPH cytochrome P450 
reductase. It was first necessary to establish the 
specificity of the immunoprecipitation technique 
for NADPH cytochrome P450 reductase. A single 
polypeptide of M, 76 000, the same as that of 
purified NADPH cytochrome P450 reductase [151, 
was immunoprecipitated by anti-(NADPH 
cytochrome P450 reductase) serum from the pro- 
ducts of translation in vitro of liver polyribosomes 
isolated from both PB- (fig. 2A,b,c) and un- 
treated (fig. 2A,e,f) rats. This polypeptide was not 
immunoprecipitated by non-immune serum 
(fig. 2A,d,g) or by PB P450 antiserum (fig. 1). The 
specificity of the immunoprecipitation reaction 
was further demonstrated by the ability of purified 
NADPH cytochrome P450 reductase to compete 
with the it4, 76 000 translation product from bin- 
ding sites on the NADPH cytochrome P450 reduc- 
tase antibody (fig. 2B). No competition was 
observed with increasing amounts of PB P450. 
Having established that anti-(NADPH 
cytochrome P450 reductase) serum precipitates on- 
ly NADPH cytochrome P450 reductase from the 
products of translation in vitro, the amount of 
translatable mRNA coding for this protein was 
quantitated in liver poly(A)+ RNA isolated from 
PB-, fl-NF- and un-treated rats as described for PB 
P450 mRNA. NADPH cytochrome P450 reductase 
was visibly immunoprecipitated from the transla- 
tion products of all three RNA samples (fig. 3). 
The mRNA coding for this protein represented 
0.062% of mRNA isolated from PB-treated 
animals (fig. 3A,b) and 0.03% of the mRNA 
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Fig. 2. Determination of the specificity of the immunoprecipitation of NADPH cytochrome P450 reductase from the 
products of translation in vitro. (A) Translation products (3 x lo6 acid-precipitable cpm) of polyribosomes isolated from 
the livers of PB-treated (tracks b-d) or control (tracks e-g) rats were incubated with 10 ~1 non-immune serum (tracks 
d,g) or 10 ~1 NADPH cytochrome P450 reductase antiserum (tracks b,c,e,f). Samples were processed as in section 2.5. 
Numbers give M, of marker proteins (x 10W3) (a). (B) Translation products (4 x lo6 acid-precipitable cpm) of 
polyribosomes isolated from the livers of PB-treated rats were mixed with the stated quantities of purified NADPH 
cytochrome P450 reductase (0) or purified PB P450 (0). Samples were incubated with 10 ~1 NADPH cytochrome P450 
reductase antiserum and processed as in section 2.5. Regions of the gel corresponding to M, 76 000 were excised and 
radioactivity was determined. Results are expressed as % of the radioactivity immunoprecipitated in the absence of any 
competitor. 
isolated from control (fig. 3A,a) or ,&-NF-treated 
animals (fig. 3A,c). The amount of translatable 
mRNA coding for NADPH cytochrome P450 
reductase was therefore increased -2-fold follow- 
ing PB-treatment and remained unchanged when 
rats were treated with /?-NF. 
To eliminate the possibility that the differential 
effect of PB and ,&NF on the amount of mRNA 
coding for NADPH cytochrome P450 reductase 
could be due to differences in the recovery of 
poly(A)+ RNA (for example, due to differences in 
poly(A) tail-length) the experiment was repeated 
on the products of translation in vitro of total 
RNA isolated from PB-, ,&NF- and un-treated 
animals (fig. 3B). Essentially the same result was 
obtained and NADPH cytochrome P450 reductase 
mRNA represented 0.063%, 0.028% and 0.027% 
of total RNA isolated from PB-treated (fig. 3B,b), 
control (fig. 3B,c) or ,&NF-treated (fig. 3B,a) 
animals, respectively. 
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abc d 
Fig. 3. SDS-polyacrylamide gel-electrophoresis demonstrating the differential effect of PB and ,&NF on translatable 
NADPH cytochrome P450 reductase mRNA. Translation products (5 x lo6 acid-precipitable cpm) of poly(A)+ RNA 
(A) or total RNA (B) isolated from the livers of ,&NF- (a), PB- (b) or un-treated (c) rats were incubated with 10 81 
NADPH cytochrome P450 reductase antiserum. Samples were processed as in section 2.5. Numbers give M, of the 
marker proteins (x 10m3) (d). 
4. DISCUSSION 
Treatment with &NF decreases the amount of 
PB P450 in microsomal membranes [8]. Here, we 
demonstrate that &NF treatment causes a cor- 
responding decrease in the level of the translatable 
mRNA coding for this protein. This suggests that 
the decrease of PB P450, in response to,&NF is not 
due entirely to a passive ‘dilution’ of the protein 
caused by a proliferation of microsomal mem- 
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branes following xenobiotic treatment, but it in- 
volves a direct effect on PB P450 gene expression. 
The decrease of PB P450 mRNA by&NF is unlike- 
ly to be due to some non-specific difference bet- 
ween the mRNA population isolated from ,&NF- 
treated and control rats because no difference was 
found in the amount of NADPH cytochrome P450 
mRNA present in these mRNA preparations. 
The results demonstrate that the increase in the 
amount of NADPH cytochrome P450 reductase in 
microsomal membranes [lo] caused by PB- 
treatment is mediated by an increase in the amount 
of translatable mRNA coding for this protein. An 
increase in NADPH cytochrome P450 reductase 
mRNA in response to PB-treatment was also 
reported in [ 16,171. ,&NF had no effect on the 
amount of NADPH cytochrome P450 reductase 
mRNA, indicating that in addition to inducing dif- 
ferent cytochrome P450 variants, PB and &NF 
have different effects on the expression of the 
genes for NADPH cytochrome P450 reductase. 
The finding that PB increases the mRNAs 
coding for PB P450 and NADPH cytochrome 
P450 reductase to very different extents suggests 
that differences may exist in the molecular pro- 
cesses involved in the induction of these two 
mRNAs. However, in microsomal membranes, the 
molecular ratio of total cytochrome 
P450: NADPH cytochrome P450 reductase is not 
changed by PB-treatment [lo]. 
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